Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 675-681

  Kaku, K ^a   Enya, K ^b   Nakaya, R ^b   Ohira, T ^b   Matsuno, R ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Fasiglifam; GPR40; Japanese patients; TAK 875; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C PEPTIDE; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PLACEBO; ANTIDIABETIC AGENT; BENZOFURAN DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONE; TAK-875;

ADENOMYOMATOSIS; ADULT; ARTICLE; BILIARY TRACT DISEASE; BODY MASS; CONTROLLED STUDY; DIET; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EPIGASTRIC PAIN; EXERCISE; FEMALE; GALLSTONE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; JAPAN; JAPANESE (PEOPLE); KIDNEY CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; AGED; AGONISTS; ANALYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; MIDDLE AGED;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOFURANS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; SULFONES;

EID: 84931956659     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12467     Document Type: Article

References (28)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 13: 4-14.
2. Sturm R. Stemming the global obesity epidemic: what can we learn from data about social and economic trends? Public Health 2008; 122: 739-746.
3. Hill JO, Wyatt HR, Reed GW etal. Obesity and the environment: where do we go from here? Science 2003; 299: 853-855.
4. DeFronzo RA. From the triumpherate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
5. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 0000. Available from URL: http://www.idf.org/guidelines/type-2-diabetes. Accessed 22 June 2013.
6. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
7. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
8. Qaseem A, Humphrey LL, Sweet DE, on behalf of the Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012; 156: 218-231.
9. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46.
10. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007; 68: 10-15.
11. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
12. Arai K, Matoba K, Hirao K etal. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
13. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerging Drugs 2013; 18: 245-258.
14. Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10: 503-512.
15. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15: 297-303.
16. Leese GP, Wang J, Broomhall J etal. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-1180.
17. Itoh Y, Kawamata Y, Harada M etal. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 2003; 422: 173-176.
18. Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 2008; 60: 405-417.
19. Bailey CJ. Could FFAR1 assist insulin secretion in type 2 diabetes? Lancet 2012; 379: 1370-1371.
20. Negoro N, Sasaki S, Mikami S etal. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010; 1: 290-294.
21. Naik H, Vakilynejad M, Wu J etal. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012; 52: 1007-1016.
22. Leifke E, Naik H, Wu J etal. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in patients with type 2 diabetes. Clin Pharmacol Ther 2012; 92: 29-39.
23. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 271-278.
24. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013; 36: 245-250.
25. Burant C, Viswanathan P, Marcinak J etal. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403-1411.
26. Kashiwagi A, Kasuga M, Araki E, for the Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society etal. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
27. The Japan Diabetes Society. Treatment guide for diabetes 2012-2013. 0000. Available from URL: http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025_54726561746D656E745F47756964655F666F725F44696162657465735F323031322D323031332E706466. Accessed 10 June 2014.
28. Takeda Press Release. Takeda announces termination of fasiglifam (TAK-875) development. 0000. Available from URL: www.takeda.us/newsroom/press_releasedetail.aspx?year=2013&id=296. Accessed 10 June 2014.